BioBlast® - Search
Celltrion recieves approval for Ph III trials of CT-P39
Korea Biomedical Review reports Celltrion has received approval for Ph III trials of CT-P39 (proposed omalizumab biosimilar).
Results of Phase I and III trials of omalizumab candidate reported
In an interview with the Centre for Biosimilars, Celltrion’s head of marketing, Byoungseo Choi reports Phase I and III trials of Celltrion’s omalizumab candidate are ongoing, and are expected to conclude by 2022.
Results of Ph 1 trials of BP001 released
BiosanaPharma releases the results of Ph I trials of BP001 (omalizumab), reporting comparability to Xolair®.
Celltrion announces the launch of Clinical trials of omalizumab biosimilar
Celltrion announces start of Phase I Clinical trials of omalizumab biosimilar, with Phase III trials expected to begin in the first half of 2020.
Phase I trials of biosimilar omalizumab approved
Biosana announces approval for Phase 1 trials of biosimilar omalizumab, with results expected in the fourth quarter of 2019.
Phase I results of biosimilar omalizumab released
Glenmark releases Phase I results of biosimilar omalizumab, suggesting similarity in pharmacokinetic, pharmacodynamic, safety and immunogenicity profiles to Xolair®.
Clinical trials of omalizumab approved
Glenmark announces FDA approval for Phase I clinical trials of omalizumab.
Results of clinical trials of biosimilar omalizumab released
Sorrento releases results of Phase II and III clinical trials of biosimilar omalizumab, announcing the candidate STI-004 demonstrated clinical efficacy and safety.
Product specific reports based on extracts from our BioBlast® database
BioBlast® Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to recieve our updates via email.